Ventyx Biosciences, Inc.

VTYX

US92332V1070

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:14:58 2025-12-08 pm EST			5-day change	1st Jan Change
8.965 ^USD	+2.81%		-2.99%	+315.53%

Dec. 02	Ventyx Biosciences Announces Appointment to Advisory Board	CI
Dec. 02	Ventyx Biosciences, Inc. Provides an Update to Its Ongoing Phase 2 Study of Vtx2735 in Patients with Recurrent Pericarditis	CI

Ventyx provides clinical and corporate updates

Published on 12/02/2025 at 09:51 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Ventyx Biosciences, Inc.

Dec. 02	Ventyx Biosciences Announces Appointment to Advisory Board	CI
Dec. 02	Ventyx Biosciences, Inc. Provides an Update to Its Ongoing Phase 2 Study of Vtx2735 in Patients with Recurrent Pericarditis	CI
Dec. 02	Ventyx provides clinical and corporate updates	RE
Dec. 02	Ventyx Biosciences Expands Phase 2 Recurrent Pericarditis Study Into Canada, EU, UK	MT
Nov. 06	Ventyx Biosciences Q3 net loss narrows to $22.8 mln	RE
Nov. 06	Ventyx Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 05	Ventyx Biosciences Shares Rise After HC Wainwright Upgrade	MT
Nov. 05	HC Wainwright Upgrades Ventyx Biosciences to Buy From Neutral, $18 Price Target	MT
Oct. 27	Oppenheimer Raises Price Target on Ventyx Biosciences to $14 From $9, Keeps Outperform Rating	MT
Oct. 24	Ventyx Biosciences, Inc. - Special Call
Oct. 23	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
Oct. 23	Sector Update: Health Care	MT
Oct. 23	Top Midday Gainers	MT
Oct. 23	Tesla Earnings Dent Investor Sentiment, Driving Narrow Premarket Losses for US Equity Futures	MT
Oct. 23	Top Premarket Gainers	MT
Oct. 22	Ventyx Biosciences announces positive topline results from phase 2 study of VTX3232 in participants with obesity and cardiovascular risk factors	RE
Oct. 22	Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors	CI
Aug. 07	Ventyx Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Jun. 30	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 2000 Dynamic Index	CI
Jun. 30	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 3000E Value Index	CI
Jun. 30	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 3000 Index	CI
Jun. 30	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 3000E Index	CI
Jun. 30	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 2000 Value Index	CI
Jun. 30	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell Small Cap Completeness Index	CI
Jun. 30	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 2000 Index	CI

Chart Ventyx Biosciences, Inc.

Duration

Period

VTYX: Dynamic Chart

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Companyâs pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 18 - Q4 2025 Earnings Release (Projected)

More about the company